Gnosis has been selected by Nutraceutical Business & Technology (NBT) Awards as one of the four finalists in the category of the “Most Effective Strategic Product Development” for the patented and registered innovative folate derivative Quatrefolic®.
The Ceremony of the Award will take place on May 11th in Geneva, during the Vitafoods Exhibition, and the winner of each Award will be announced at a dedicated gala dinner where 200 professionals from the nutraceutical and functional foods industry will be present.
NBT Awards recognize excellence in R&D, marketing, business and technology in the areas of ingredients, finished products, applications and business practices. Quatrefolic® has been nominated according to its, strategic orientation, significant planning and project management execution performed with the alignment of the research to overcome development challenges and respond to emerging trends, new product requirements and market needs.
“We are honoured to be named for this recognition,” said Paolo Malesani, Gnosis’ Commercial Director.” A company must focus itself on what will distinguish it in the market place. The candidature of Quatrefolic® awards our constant effort to introduce solid products and new ingredient technologies with sound intellectual property to the market. This product offers both an outstanding value both of research and market opportunity”.
The independent judging panel has been selected to give an impartial, professional and wide-ranging level of expertise and is assembled exclusively from leading healthcare organizations and top business school academics.
Quatrefolic ®is a new dietary ingredient that has been developed and patented by Gnosis. It is a new generation of folate derivative and a new option to the older generation 5-methyltetrahydrofolate calcium salt, up to now the only derivative of folate able to penetrate the body cells without being metabolized. Made up of glucosamine salt of (6S)-5-methytetrahydrofolate, the new product offers the following benefits to formulators and consumers;
1- Manufactured under cGMP
2- Greater bioavailability then the 5-methytetrahydrofolate calcium salt form
3- Able to penetrate cells without being metabolized
4- Greater solubility to facilitate improved formulating flexibility
5- Greater stability to facilitate improved formulating flexibility
6- Ability to formulate in combination with vitamins and minerals
7- Proprietary (patents granting)
8- Trademark registered
The Food and Drug Administration (FDA) has recognized Quatrefolic® as a New Dietary Ingredient (NDI) in November 2010. GRAS (generally recognized as safe) status has been achieved for use in conventional and medical foods. The patented and registered Quatrefolic® is suitable for dietary supplements as well as food and beverage uses, specifically for combinations of different vitamins and minerals.
For more information visit: